- Home
- BCLI vs DSS Comparison
BCLI vs DSS Comparison
Compare BCLI & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- DSS
- Stock Information
- Founded
- BCLI 2000
- DSS 1984
- Country
- BCLI United States
- DSS United States
- Employees
- BCLI N/A
- DSS N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- DSS Containers/Packaging
- Sector
- BCLI Health Care
- DSS Consumer Discretionary
- Exchange
- BCLI Nasdaq
- DSS Nasdaq
- Market Cap
- BCLI 9.8M
- DSS 8.9M
- IPO Year
- BCLI N/A
- DSS N/A
- Fundamental
- Price
- BCLI $1.16
- DSS $0.89
- Analyst Decision
- BCLI Strong Buy
- DSS
- Analyst Count
- BCLI 1
- DSS 0
- Target Price
- BCLI $30.00
- DSS N/A
- AVG Volume (30 Days)
- BCLI 412.8K
- DSS 187.4K
- Earning Date
- BCLI 08-13-2025
- DSS 08-12-2025
- Dividend Yield
- BCLI N/A
- DSS N/A
- EPS Growth
- BCLI N/A
- DSS N/A
- EPS
- BCLI N/A
- DSS N/A
- Revenue
- BCLI N/A
- DSS $20,180,000.00
- Revenue This Year
- BCLI N/A
- DSS N/A
- Revenue Next Year
- BCLI N/A
- DSS N/A
- P/E Ratio
- BCLI N/A
- DSS N/A
- Revenue Growth
- BCLI N/A
- DSS 12.88
- 52 Week Low
- BCLI $0.72
- DSS $0.72
- 52 Week High
- BCLI $6.45
- DSS $1.67
- Technical
- Relative Strength Index (RSI)
- BCLI 49.98
- DSS 46.74
- Support Level
- BCLI $1.02
- DSS $0.88
- Resistance Level
- BCLI $1.32
- DSS $0.96
- Average True Range (ATR)
- BCLI 0.09
- DSS 0.07
- MACD
- BCLI -0.00
- DSS -0.00
- Stochastic Oscillator
- BCLI 46.67
- DSS 41.67
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.